NRG Therapeutics Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
24
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$66.9M
- Investors
-
17
NRG Therapeutics General Information
Description
Developer of a drug discovery platform intended to develop therapeutic approaches to restore mitochondrial function. The company's platform utilizes small-molecule inhibitors and nlrx1 protein targeting to address neurodegenerative pathology, enabling physicians and pharmaceutical partners to treat parkinson's and amyotrophic lateral sclerosis through a specialized digital and physical therapeutic ecosystem.
Contact Information
Website
www.nrgtherapeutics.comCorporate Office
- Stevenage Bioscience Catalyst
- Gunnels Wood Road, Herts
- Stevenage SG1 2FX
- England, United Kingdom
Corporate Office
- Stevenage Bioscience Catalyst
- Gunnels Wood Road, Herts
- Stevenage SG1 2FX
- England, United Kingdom
NRG Therapeutics Timeline
NRG Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series B) | 08-Sep-2025 | $66.9M | Completed | Clinical Trials - Phase 1 | ||
| 8. Grant | 31-Oct-2024 | Completed | Clinical Trials - Phase 1 | |||
| 7. Later Stage VC | 14-May-2024 | Completed | Clinical Trials - Phase 1 | |||
| 6. Grant | 22-Feb-2023 | Completed | Clinical Trials - Phase 1 | |||
| 5. Early Stage VC (Series A) | 01-Nov-2022 | Completed | Clinical Trials - Phase 1 | |||
| 4. Grant | 30-May-2022 | Completed | Clinical Trials - Phase 1 | |||
| 3. Seed Round | 23-Aug-2021 | Completed | Clinical Trials - Phase 1 | |||
| 2. Grant | 29-Jul-2021 | $500K | $2.54M | Completed | Clinical Trials - Phase 1 | |
| 1. Seed Round | 03-Aug-2020 | $2.54M | $2.54M | Completed | Startup |
NRG Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A2 | ||||||||
| Series A1 | 407,925 | $0.000135 | $5.35 | $5.35 | 1x | $5.35 | 5.26% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
NRG Therapeutics Comparisons
Industry
Financing
Details
NRG Therapeutics Competitors (4)
One of NRG Therapeutics’s 4 competitors is Neuro-Bio, a Venture Capital-Backed company based in Abingdon, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Neuro-Bio | Venture Capital-Backed | Abingdon, United Kingdom | ||||
| Aquinnah | Venture Capital-Backed | Cambridge, MA | ||||
| Mission Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Alchemab Therapeutics | Venture Capital-Backed | London, United Kingdom |
NRG Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
NRG Therapeutics Patents
NRG Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202410534-D0 | Novel method and uses | Inactive | 18-Jul-2024 | ||
| WO-2026018015-A2 | Novel methods and uses | Pending | 18-Jul-2024 | ||
| WO-2026018015-A3 | Novel methods and uses of ligands of nlrx1 | Pending | 18-Jul-2024 | ||
| EP-4774033-A1 | Pyridine derivatives which act as inhibitors of mptp | Pending | 05-Sep-2023 | ||
| WO-2025052129-A1 | Pyridine derivatives which act as inhibitors of mptp. | Inactive | 05-Sep-2023 | A61P25/28 |
NRG Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
NRG Therapeutics Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| British Business Bank | Lender/Debt Provider | Minority | ||
| Caixa Capital Risc | Corporate Venture Capital | Minority | ||
| Criteria Bio Ventures | Venture Capital | Minority | ||
| M Ventures | Corporate Venture Capital | Minority | ||
| SV Health Investors | PE/Buyout | Minority |
NRG Therapeutics FAQs
-
When was NRG Therapeutics founded?
NRG Therapeutics was founded in 2018.
-
Where is NRG Therapeutics headquartered?
NRG Therapeutics is headquartered in Stevenage, United Kingdom.
-
What is the size of NRG Therapeutics?
NRG Therapeutics has 24 total employees.
-
What industry is NRG Therapeutics in?
NRG Therapeutics’s primary industry is Drug Discovery.
-
Is NRG Therapeutics a private or public company?
NRG Therapeutics is a Private company.
-
What is the current valuation of NRG Therapeutics?
The current valuation of NRG Therapeutics is .
-
What is NRG Therapeutics’s current revenue?
The current revenue for NRG Therapeutics is .
-
How much funding has NRG Therapeutics raised over time?
NRG Therapeutics has raised $95M.
-
Who are NRG Therapeutics’s investors?
British Business Bank, Caixa Capital Risc, Criteria Bio Ventures, M Ventures, and SV Health Investors are 5 of 17 investors who have invested in NRG Therapeutics.
-
Who are NRG Therapeutics’s competitors?
Neuro-Bio, Aquinnah, Mission Therapeutics, and Alchemab Therapeutics are competitors of NRG Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
